{
    "Trade/Device Name(s)": [
        "VITEK 2 AST-Gram Positive Delafloxacin",
        "VITEK 2 AST-GP Delafloxacin"
    ],
    "Submitter Information": "bioM\u00e9rieux, Inc.",
    "510(k) Number": "K200590",
    "Predicate Device Reference 510(k) Number(s)": [
        "K190616"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LON",
        "LTT",
        "LTW"
    ],
    "Summary Letter Date": "March 4, 2020",
    "Summary Letter Received Date": "March 6, 2020",
    "Submission Date": "March 4, 2020",
    "Regulation Number(s)": [
        "21 CFR 866.1645"
    ],
    "Regulation Name(s)": [
        "Fully Automated Short-Term Incubation Cycle Antimicrobial Susceptibility System"
    ],
    "Analyte Class(es)": [
        "microbiology"
    ],
    "Analyte(s)": [
        "Delafloxacin"
    ],
    "Specimen Type(s)": [
        "Gram positive microorganisms"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "VITEK 2",
        "VITEK 2 Compact"
    ],
    "Method(s)/Technology(ies)": [
        "Automated quantitative antimicrobial susceptibility test",
        "Microdilution minimum inhibitory concentration (MIC) technique"
    ],
    "Methodologies": [
        "Growth Pattern Analysis",
        "Broth microdilution"
    ],
    "Submission Type(s)": [
        "Reagent",
        "Panel",
        "Automated system"
    ],
    "Document Summary": "FDA 510(k) summary for VITEK 2 AST-Gram Positive Delafloxacin panel for automated antimicrobial susceptibility testing of Gram positive microorganisms.",
    "Indications for Use Summary": "Laboratory aid for in vitro quantitative determination of susceptibility of Gram positive microorganisms to Delafloxacin using VITEK 2 and VITEK 2 Compact Systems; applicable to Staphylococcus aureus (including MRSA/MSSA), Streptococcus agalactiae, Enterococcus faecalis for skin/skin structure infections and community-acquired bacterial pneumonia.",
    "fda_folder": "Microbiology"
}